Fat loss
13 peptides in this category.
Semaglutide
Ozempic · Wegovy
The GLP-1 receptor agonist that turned obesity pharmacology into a mainstream conversation. Once-weekly injection, ~7-day half-life, and the largest randomised dataset of anything in this catalogue.
ViewTirzepatide
Mounjaro · Zepbound
Dual GIP and GLP-1 agonist. Beats Semaglutide head-to-head on weight loss and glycaemic control, and is becoming the default first-line choice when both are available.
ViewRetatrutide
LY3437943
Triple agonist hitting GIP, GLP-1, and glucagon receptors at once. Phase 2 data shows the largest weight-loss numbers ever reported for a drug in trials — ~24% at 48 weeks.
ViewMazdutide
IBI362 · LY3305677
Chinese-developed GLP-1 / glucagon co-agonist (IBI362, licensed from Eli Lilly's LY3305677). Solid Phase 2 data, approved in China for diabetes in 2024, investigational elsewhere.
ViewCagriSema
CagriSema · Cagrilintide + Semaglutide
Once-weekly fixed-dose combination of Cagrilintide and Semaglutide. The leading 'next-generation' obesity treatment in Phase 3, delivering roughly 20% weight loss in late trials.
ViewCagrilintide
AM833
Long-acting amylin analogue for once-weekly dosing. Useful on its own; dramatically more useful paired with Semaglutide as the CagriSema combination.
ViewAOD9604
Anti-Obesity Drug 9604
A short fragment of human growth hormone (residues 177-191) that was sold the lipolytic tail of HGH without the growth signal. The marketing outpaced the trial data by a wide margin.
View5-Amino-1MQ
5-amino-1-methylquinolinium · NNMT inhibitor
An orally bioavailable small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase). Plenty of compelling rodent data, almost no human data, and a forum community that has gotten ahead of the science.
ViewLipo-C (MIC)
Lipo-C · MIC blend
A vitamin-and-amino-acid injection blend - methionine, inositol, choline, B12, sometimes more. It is not a peptide and it is not a fat-burner. It is an old-school clinic adjunct with decades of use and almost no RCT support.
ViewSurvodutide
Survodutide
Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist. Phase 2 weight loss in the 15–19% range, with a notable side-effect on liver fibrosis in NASH patients.
ViewFat Blaster
L-Carnitine + B-vitamin blend
Lipo-C's training-focused cousin: the same B-vitamin core plus L-carnitine to support fatty-acid transport into mitochondria. Old-school clinic blend, not a peptide, and the trial data is thin.
ViewLemon Bottle
Lipolytic Solution
A localised cosmetic fat-dissolving injectable - riboflavin, lecithin, bromelain - applied by aestheticians to small fat pockets like the submental area, jawline, or love handles. Contouring tool, not a weight-loss treatment.
ViewSLU-PP-332
SLU-PP-332
A small-molecule pan-agonist of estrogen-related receptors (ERR alpha/beta/gamma) developed academically. In mice, it produces exercise-like adaptations and meaningful fat loss. In humans, there is zero clinical data. Treat it as the experimental tool it actually is.
View